SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present updated
clinical data from its phase 2 Investigator Sponsored Trial
assessing the combination of OncoSec's investigational therapy,
ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene
telseplasmid or "tavo"] with electroporation), and the approved
anti-PD-1 therapy pembrolizumab, in patients with unresectable
metastatic melanoma. The late-breaking poster presentation will
occur at the upcoming Society for Immunotherapy of Cancer ("SITC")
32nd Annual Meeting to be held on November 8-12, 2017, in National Harbor, MD. In
addition, OncoSec will present preclinical data from its novel
multi-gene expression platform termed PIIM (Polycistronic
Interleukin-12 Immune Modulator) as a
poster presentation at the same meeting.
"We are pleased that the Society for Immunotherapy of Cancer
will highlight updated clinical data from our phase 2 study that
led us to initiate our global, open-label, registration directed
phase 2b clinical trial, PISCES/KEYNOTE-695, which will evaluate
the combination of ImmunoPulse IL-12 and pembrolizumab in
metastatic melanoma patients who are progressing or have progressed
on anti-PD-1," said Punit Dhillon,
CEO and President at OncoSec. "We remain committed to excelling in
scientific innovation and clinical development and look forward to
sharing data from our recently initiated study in mid-2018."
The late-breaking poster presentation details are as
follows:
Title: Clinical and biomarker analyses of a phase II
study of intratumoral tavokinogene telseplasmid (pIL-12) plus
pembrolizumab in stage III/IV melanoma patients predicted to not
respond to anti-PD-1
Poster Number: P524
Lead Author: Alain Algazi,
MD, Associate Professor, Department of Medicine
(Hematology/Oncology), UCSF
Date and Time: Saturday, November
11th, 12:30-2:00
p.m. and 6:30-8:00 p.m.
Location: Gaylord National Resort & Convention
Center
For more information about this trial, please visit:
https://clinicaltrials.gov/ct2/show/NCT02493361?term=pIL-12&rank=3
The poster presentation details are as follows:
Title: Intratumoral administration of a multigene
construct by electroporation can effectively modulate anti-tumor
response in a murine B16.F10 model
Poster Number: P403
Lead Author: Shawna
Shirley, Ph.D., Senior Scientist, OncoSec
Session Title: Oncolytic Viruses and Intratumoral
Therapies
Date and Time: Friday, November
10th, 12:30-2:00
p.m. and 6:30-8:00 p.m.
Location: Gaylord National Resort & Convention
Center
Per SITC guidelines, abstracts are embargoed until 8:00 a.m. EST on November
7, 2017. To view abstracts, please visit the SITC
website at https://www.sitcancer.org/2017/abstracts/info.
ImmunoPulse® is a registered trademark of OncoSec Medical
Incorporated, San Diego, CA,
USA.
About the SITC Annual Meeting
The Society for Immunotherapy of Cancer (SITC) is a non-profit
medical professional society of influential scientists,
academicians, researchers, clinicians, government representatives,
and industry leaders from around the world dedicated to improving
cancer patient outcomes by advancing the science and application of
cancer immunotherapy. Currently, SITC has nearly 1,600
members representing 17 medical specialties and are engaged in
research and treatment of at least a dozen types of cancer. The
32nd SITC Annual Meeting & Associated Programs will
take place November 8-12, 2017 at the
Gaylord National Hotel & Convention Center in National Harbor,
MD. For more information, please go to
http://www.sitcancer.org/2017.
About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination
Electroporation Study)
PISCES is a global, multicenter phase
2b, open-label trial of intratumoral plasma encoded IL-12
(tavokinogene telseplasmid or "tavo") delivered by electroporation
in combination with intravenous pembrolizumab in patients with
stage III/IV melanoma who have progressed or are progressing on
either pembrolizumab or nivolumab treatment. The Simon 2-stage
study of intratumoral tavo plus electroporation in combination with
pembrolizumab will enroll approximately 48 patients with
histological diagnosis of melanoma with progressive locally
advanced or metastatic disease defined as Stage III or Stage IV.
The primary endpoint will be the Best Overall Response Rate
(BORR).
About OncoSec Medical Incorporated:
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed
to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 (delivering pIL-12 referred to as
tavokinogene telseplasmid or "tavo") has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program with tavo is currently in clinical development for
metastatic melanoma and triple-negative breast cancer. The
program's current focus with PISCES is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-acceptance-of-late-breaking-abstract-at-upcoming-society-for-immunotherapy-of-cancer-sitc-annual-meeting-2017-300535201.html
SOURCE OncoSec Medical Incorporated